Merck & Co., Inc. (MRK) CEO Ken Frazier on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 04/28/20
Why Merck's Q1 Update Disappointed Investors Despite Beating Wall Street EstimatesThe Motley Fool • 04/28/20
Earnings Buffet: A Plate Of Caterpillar, PepsiCo Now, Alphabet And Advanced Micro LaterForbes • 04/28/20
Merck Earnings Top, But Pharma Giant Cuts Guidance; Dow Stock FallsInvestors Business Daily • 04/28/20
3 Big Stock Charts for Tuesday: Johnson & Johnson, Merck, and Bristol-Myers SquibbInvestorPlace • 04/28/20
Cue Biopharma Announces Clinical Trial Collaboration Agreement with Merck to Evaluate CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment For HPV+ Recurrent/Metastatic Head and Neck CancerGlobeNewsWire • 04/20/20